Cardiac Involvement of COVID-19: A Comprehensive Review

被引:0
作者
Chang, Wei-Ting [1 ,2 ,3 ]
Toh, Han Siong [2 ,4 ]
Liao, Chia-Te [1 ,5 ]
Yu, Wen-Liang [4 ,6 ]
机构
[1] Chi Mei Med Ctr, Dept Internal Med, Div Cardiol, Tainan, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan
[3] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan
[4] Chi Mei Med Ctr, Dept Intens Care Med, 901 Chung Hwa Rd, Tainan 710, Taiwan
[5] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan, Taiwan
[6] Taipei Med Univ, Coll Med, Sch Med, Dept Med, Taipei, Taiwan
关键词
Coronavirus; Covid-19; Sars-cov-2; Myocardial injury; myocarditis; CORONAVIRUS DISEASE 2019; CLINICAL CHARACTERISTICS; MYOCARDIAL INJURY; SYSTEM INHIBITORS; MANAGEMENT; STATEMENT; WUHAN; SARS-COV-2; PNEUMONIA;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. SARS-CoV-2 caused COVID-19 has reached a pandemic level. COVID-19 can significantly affect patients' cardiovascular systems. First, those with COVID-19 and preexisting cardiovascular disease have an increased risk of severe disease and death. Mortality from COVID-19 is strongly associated with cardiovascular disease, diabetes, and hypertension. Second, therapies under investigation for COVID-19 may have cardiovascular side effects of arrhythmia. Third, COVID-19 is associated with multiple direct and indirect cardiovascular complications. Associated with a high inflammatory burden related to cytokine release, COVID-19 can induce vascular inflammation, acute myocardial injury, myocarditis, arrhythmias, venous thromboembolism, metabolic syndrome and Kawasaki disease. Understanding the effects of COVID-19 on the cardiovascular system is essential for providing comprehensive medical care for cardiac and/or COVID-19 patients. We hereby review the literature on COVID-19 regarding cardiovascular virus involvement.
引用
收藏
页码:14 / 22
页数:9
相关论文
共 88 条
[1]  
[Anonymous], 2020, CHINESE MED J-PEKING, DOI DOI 10.1097/CM9.0000000000000824
[2]  
[Anonymous], 2020, THROMB RES
[3]   Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State [J].
Arentz, Matt ;
Yim, Eric ;
Klaff, Lindy ;
Lokhandwala, Sharukh ;
Riedo, Francis X. ;
Chong, Maria ;
Lee, Melissa .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (16) :1612-1614
[4]  
Asif Talal, 2020, Eur J Case Rep Intern Med, V7, P001701, DOI [10.12890/2020_001672, 10.12890/2020_001701]
[5]  
Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI [10.1056/NEJMoa2007764, 10.1056/NEJMc2022236]
[6]   Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 [J].
Bozkurt, Biykem ;
Kovacs, Richard ;
Harrington, Bob .
JOURNAL OF CARDIAC FAILURE, 2020, 26 (05) :370-370
[7]   Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System JACC Review Topic of the Week [J].
Brojakowska, Agnieszka ;
Narula, Jagat ;
Shimony, Rony ;
Bander, Jeffrey .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (24) :3085-3095
[8]   Takotsubo Cardiomyopathy Triggered by Influenza A Virus [J].
Buzon, Julie ;
Roignot, Ombeline ;
Lemoine, Simon ;
Perez, Pierre ;
Kimmoun, Antoine ;
Levy, Bruno ;
Novy, Emmanuel .
INTERNAL MEDICINE, 2015, 54 (16) :2017-2019
[9]   Cardiac toxicity secondary to long term treatment with chloroquine [J].
Cervera, A ;
Espinosa, G ;
Cervera, R ;
Font, J ;
Ingelmo, M .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (03) :301-301
[10]   SARS-CoV-2: a potential novel etiology of fulminant myocarditis [J].
Chen, Chen ;
Zhou, Yiwu ;
Wang, Dao Wen .
HERZ, 2020, 45 (03) :230-232